Organisation paid for research Program year 2025 Source: CMS Open Payments

Chemidox Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$743,498

36 payments

Through program year 2025, Chemidox Clinical Trials is reported as receiving $743,498 in research payments, across 36 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $114,962 24
2024 Research $1,717 3
2023 Research $312,410 2
2022 Research $314,410 7

Breakdown

Who paid Research payments · program years 2022–2025
  1. Merck Sharp & Dohme Corporation $608,514 7 payments
  2. Sanofi Pasteur Inc. $86,940 11 payments
  3. Cleerly, Inc. $26,276 6 payments
  4. Pfizer Inc. $21,767 12 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults $607,162 6 payments
  2. A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2-arm Study to Investigate the Safety and Immunogenicity of a 4-dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers $76,140 7 payments
  3. Transform $26,276 6 payments
  4. A Phase 1 Openlabel Study to Evaluate the Pharmacokinetics Safety and Tolerability of Orally Administered Nirmatrelvirritonavir in Pregnant Women With Mildtomoderate Covid19 $19,894 4 payments
  5. Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) $10,800 4 payments
  6. A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na ve Adults $1,353 1 payment
  7. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $1,070 4 payments
  8. A Phase 3 Randomized Placebocontrolled Doubleblinded Trial to Evaluate the Safety Tolerability and Immunogenicity of A Multivalent Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Infants $675 3 payments
  9. A Phase 1 Openlabel Study to Evaluate the Pharmacokinetics Safety and Tolerability of Orally Administered Nirmatrelvirritonavir in Pregnant Women With Mildtomoderate Covid19 $128 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record